Examining Neuropsychiatric Disorders in Survivors of COVID-19-Related Critical Illness
S
Sophia Wang, MD
Primary Investigator
Overview
There is growing concern about the high rate of reported neuropsychiatric symptoms in COVID-19 “long haulers.” Survivors of COVID-19-related critical illness may be particularly susceptible to these neuropsychiatric disorders. This study seeks to collect neuroimaging, blood, and cognitive and functional measures to better understand how COVID-19 infection may lead to neuropsychiatric disorders in critically ill survivors.
Description
Participants will have blood drawn while in the hospital about 1 week after being admitted. Approximately 1.5 tablespoons of blood will be collected.
Participants will complete one study visit around the time of hospital discharge. The study visit takes approximately one hour and includes thinking and memory activities, questionnaires about mood, memory, health, medications and daily activities; and measurements of muscle strength (ability to stand from a sitting position), balance and walking.
Approximately six months after hospital discharge, participants will complete a second study visit repeating the same activities and a blood draw.
Certain eligible participants may be invited to complete an optional brain scan called a magnetic resonance image (MRI) during study visits.
Eligibility
You may be eligible for this study if you meet the following criteria:
-
Conditions:
COVID-19, long haulers
-
Age: Between 18 Years - 100 Years
-
Gender: All
Inclusion Criteria:
- Admitted to the hospital for critical illness for ≥ 24 hours
- Proficiency in English and willing to participate in cognitive testing
- No visual or hearing impairments which will interfere with cognitive testing (devices or equipment to correct impairments are allowed)
- Critical illness due to acute respiratory failure or shock
- An admission diagnosis of either 1) severe COVID-19 symptoms if PCR-confirmed SARS-CoV-2 infection or 2) acute respiratory failure (ARF) or shock if PCR is negative for SARS-CoV-2 infection
- MRI participants: must be 50 and older and willing and eligible to participate in 3T brain MRI based on a standardized MRI safety checklist
Exclusion Criteria:
- History of severe mental illness (psychosis, mania, or severe depression)
- History of neurodegenerative disorder (including but not limited to Alzheimer’s disease, Parkinson’s disease, and vascular dementia) and/or are taking dementia treatments
- Admission for alcohol-related delirium
- Admission for or a history of a diagnosis of a central nervous disorder (e.g. ischemic stroke, hemorrhagic stroke, moderate or severe traumatic brain injury, primary or metastatic central nervous neoplasms), infection (e.g. encephalitis, meningitis, or intracerebral abscess), or neurosurgical intervention
- Immunocompromised patients with central nervous system sequelae (e.g. human immunodeficiency virus (HIV) positive patients with current CD4 count ≤ 200 and patients on chemotherapy)
- Life expectancy less than 1 year
- Recent history of alcohol > 5 drinks per day or substance abuse consistently over the last 3 months
- Status post tracheostomy and not eligible for a speaking valve
- Incarcerated at the time of study enrollment
- Homelessness
- Illiterate
- Legally blind
- Pregnant or nursing
Updated on
02 May 2024.
Study ID: 11444, PSYC-IIR-EN-COV
Please visit our main page to search for other studies you may be interested in.
If you need help finding a study or have any questions, please contact us at inhealth@iu.edu
